Inhibition of mouse retroviral disease by bioactive glutaminase-asparaginase

References

1. Anderson-Berg W. T., Squire R. A., Strand M. 1987; Specific radioimmunotherapy using ⁹⁰Y-labeled monoclonal antibody in erythroleukemic mice. Cancer Research 47:1905–1912
   [Google Scholar]
2. Boiron M., Levy J. P., Lasneret J., Oppenheim S., Bernard J. 1965; Pathogenesis of Rauscher leukemia. Journal of the National Cancer Institute 35:865–884
   [Google Scholar]
3. Chirigos M. A. 1964; Studies with the murine leukemogenic Rauscher virus. III. An in vivo assay for anti-viral agents. Cancer Research 24:1035–1041
   [Google Scholar]
4. Falk L. A., Paul D., Landay A., Kessler H. 1987; HIV isolation from plasma of HIV-infected persons. New England Journal of Medicine 316:1547–1548
   [Google Scholar]
5. Feng Y. -X., Hatfield D. L., Rein A., Levin J. 1989; Translational readthrough of the murine leukemia virus gag gene amber codon does not require virus-induced alteration of tRNA. Journal of Virology 63:2405–2410
   [Google Scholar]
6. Gloger I., Panet A. 1986; Glutamine starvation of murine leukaemia virus-infected cells inhibits read through of the gag-pol genes and proteolytic processing of the gag polyprotein. Journal of General Virology 67:2207–2213
   [Google Scholar]
7. Gloger I., Arad G., Panet A. 1985; Regulation of Moloney murine leukemia virus replication in chronically infected cells arrested at the G₀/G₁ phase. Journal of Virology 54:844–850
   [Google Scholar]
8. Gregerson J. P., Wege H., Preiss L., Jentsch K. D. 1988; Detection of human immunodeficiency virus and other retroviruses in cell culture supernatants by a reverse transcriptase microassay. Journal of Virological Methods 19:161–168
   [Google Scholar]
9. Hartley J. W., Fredrickson T. N., Yetter R. A., Makino M., Morse H. C. 1989; Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. Journal of Virology 63:1223–1231
   [Google Scholar]
10. Hershfield M. S., Buckley R. H., Greenberg M. L., Melton A. L., Schiff R., Hatem C., Kurtzberg J., Markert M. L., Kobayashi R. H., Kobayashi A. L., Abuchowski A. 1987; Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. New England Journal of Medicine 310:589–596
    [Google Scholar]
11. Holcenberg J. S. 1981; Therapy of neoplasia with other nonessential amino acid degrading enzymes. In Enzymes as Drugs pp. 25–61 Edited by Holcenberg J. S., Roberts J. New York: John Wiley;
    [Google Scholar]
12. Jacks T., Power M. D., Masiarz F. R., Lucin P. A., Barr P. J., Varmus H. E. 1988; Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature, London 331:280–283
    [Google Scholar]
13. Kuchino Y., Nishimura S., Schröder H. Z., Rottmann M., Müller W. E. G. 1988; Selective inhibition of formation of suppressor glutamine tRNA in Moloney murine leukemia virus-infected NIH-3T3 cells by avarol. Virology 165:518–526
    [Google Scholar]
14. Kurtzberg J., Moore J. O., Scudiery D., Franklin A. 1988; A phase II study of polyethylene glycol (PEG) conjugated l-asparaginase in patients with refractory acute leukemias. Proceedings of the American Association for Cancer Research 29:213
    [Google Scholar]
15. McGregor W. G., Roberts J. 1989; Glutaminase enhances therapeutic effectiveness of glutamine antimetabolites against human and murine solid tumors in vivo . Proceedings of the American Association for Cancer Research 30:578
    [Google Scholar]
16. Marks P. A., Rifkind R. A. 1978; Erythroleukemic differentiation. Annual Review of Biochemistry 47:419–448
    [Google Scholar]
17. Mita S., Chou T. C., Roberts J., Steinherz P., Miller D., Tan C. 1980; Phase I trial of succinylated Acinetobacter glutaminase–asparaginase (SAGA) in children. Proceedings of the American Association for Cancer Research 21:143
    [Google Scholar]
18. Müller W. E. G., Schröder H. C., Reuter P., Sarin P. S., Hess G., Meyer K. H., Zum Büschenfelde M., Kuchino Y., Nishimura S. 1988; Inhibition of expression of natural UAG suppressor glutamine tRNA in HIV-infected human H9 cells in vitro by avarol. Aids Research and Human Retroviruses 4:279–286
    [Google Scholar]
19. O’Donnell P. V., Stockert E., Obata Y., Old L. J. 1981; Leukemogenic properties of AKR dualtropic (MCF) viruses: amplification of murine leukemia virus-related antigens on thymocytes and acceleration of leukemia development in AKR mice. Virology 112:548–563
    [Google Scholar]
20. Panganiban A. T. 1988; Retroviral gag gene amber codon suppression is caused by an intrinsic cis-acting component of the viral mRNA. Journal of Virology 62:3574–3580
    [Google Scholar]
21. Rauscher F. J. 1962; A virus-induced disease of mice characterized by erythropoiesis and lymphoid leukemia. Journal of the National Cancer Institute 29:515–543
    [Google Scholar]
22. Roberts J. 1976; Purification and properties of a highly potent antitumor glutaminase-asparaginase from Pseudomonas 7A . Journal of Biological Chemistry 251:2119–2123
    [Google Scholar]
23. Roberts J., McGregor W. G. 1989; Glutaminase has potent antiretroviral activity in vivo . Proceedings of the American Association for Cancer Research 30:454
    [Google Scholar]
24. Roberts J., Rosenfeld H. 1980; Enhancement of antineoplastic activity of the glutamine antagonists DON and AT-125 by glutaminase–asparaginase. Proceedings of the American Association for Cancer Research 21:283
    [Google Scholar]
25. Roberts J., Schmid F. A., Rosenfeld H. 1979; Biologic and antineoplastic effects of enzyme-mediated in vivo depletion of l-glutamine, l-tryptophan, and l-histidine. Cancer Treatment Reports 63:1045–1054
    [Google Scholar]
26. Rosenfeld H., Roberts J. 1981; Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-l-norleucine and Acivicin in cell culture by glutaminase-asparaginase. Cancer Research 41:1324–1328
    [Google Scholar]
27. Rowe W. P., Pugh W. E., Hartley J. W. 1970; Plaque assay techniques for murine leukemia viruses. Virology 42:1136–1139
    [Google Scholar]
28. Ruprecht R. M., O’Brien L. G., Rossoni L. D., Nusinoff-Lehrmann S. 1986; Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature, London 323:467–469
    [Google Scholar]
29. Varmus H. 1989; Lessons from the life cycle of retroviruses. The Harvey Lectures 83:35–56
    [Google Scholar]
30. Yoshinaka Y., Katoh I., Copeland T. D., Oroszlan S. 1985; Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through repression of an amber termination codon. Proceedings of the National Academy of Sciences, U.S.A. 82:1618–1622
    [Google Scholar]